China Drug Registration Proposal Requires Clinical Trials For Follow-On Biologics – Sidley Austin
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S.-based law firm also advises China to incorporate international standards for pharmacovigilance and adopt GMPs for APIs, in comments submitted to China’s SFDA.